Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 232, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.114164
Keywords
Quinazolin-4-amine; Coumarin; Chikungunya virus; Hepatitis C virus; Broad-spectrum; Structure-activity relationship
Categories
Funding
- Ministry of Science and Technology (MOST) [110-2113-M-007-011, 110-2634-F-007-023]
- Ministry of Education [110QR001I5, 109QR001I5]
- European Commission SILVER project within the 7th Framework Programme as Cooperation Project [260644]
Ask authors/readers for more resources
The development of new drugs with broad-spectrum activity against RNA viruses is of great significance for mankind, but it is also faced with significant challenges. In this study, a series of quinazolin-4-amine-SCH2-coumarin conjugated compounds were designed and synthesized, and their anti-viral activities against chikungunya virus and hepatitis C virus were evaluated using virus-cell-based assays.
Development of new drugs with broad-spectrum to combat RNA viruses would be beneficial to mankind but faces a great challenge. We designed and efficiently synthesized a series of quinazolin-4-amine-SCH2-coumarin conjugated compounds. Our data of the virus-cell-based assay show five new conjugates inhibit chikungunya virus with EC50 values as potent as 1.96 mu M and two conjugates inhibit hepatitis C virus with EC50 values as low as 16.6 mu M. These conjugates possess a xylene substituent at the C-4 amino group of quinazoline and a t-butyl substituent at the C-6' position of coumarin. (c) 2022 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available